Shares of Bionik Laboratories Corp (OTCMKTS:BNKL) continues to trade in a narrow range after the recent gains.
On Thursday, BNKL stock ended flat at $2 with more than 27 shares, compared to its average volume of 248 shares. The stock has moved within a range of $2.0000 – 2.0000 after opening the trade at $1.90.
to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
Robotics company focusing on rehabilitation and assistive technology solutions to individuals with mobility and neurological challenges, Bionik Laboratories Corp (OTCMKTS:BNKL), on November 11, 2021 announced participation in MEDICA Trade Show in Dusseldorf, Germany from November 15–18, 2021.
World forum of medical industry, MEDICA, brings together in medical equipment and technologies. The company will have a booth at Hall 4- 4H46 –Physiotherapy and Orthopedicsand showcase its InMotion Robotic Therapy Systems.
At the forum, the company will be highlighting its ability to deliver therapy for helping patients get motor function following stroke or neurological conditions.
Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Officer of BIONIK, said that MEDICA is globally the biggest medical industry event and is attended by thousands of potential buyers.
Russo said that the company’s presence at MEDICO provides opportunity for showcasing industry-leading solutions to global audience of health professionals utilising InMotion therapy systems within organizations. Russo added that the firm is keen on networking with healthcare technology community and showcasinghow solutions provide optimal patient outcomes.
InMotion therapy guides patients to improve motor control of the arm and hand by augmenting strength, range of motion as well as coordination. BIONIK will be focusing on expanding and strengthening distribution partners for InMotion.
“MEDICA is the world’s largest medical industry event, attended by thousands of potential buyers of innovative medical technologies. Our presence at MEDICA gives us the opportunity to showcase our industry-leading solutions in front of a global audience of health professionals who can utilize InMotion® therapy systems within their organizations,” said Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Officer of BIONIK. “We look forward to the opportunity to network with the global healthcare technology community, and to further showcase how our solutions provide more optimal patient outcomes while also impacting the bottom line of the healthcare facility where it is in use.”